Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01649180
Title NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)
Acronym PrE0801
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors PrECOG, LLC.
Age Groups: adult
Covered Countries USA

No variant requirements are available.